Akagera Medicines Secures Additional $7.8 Million from Gates Foundation to Advance Tuberculosis Vaccine

0
1
Daryl Drummond, Ph.D.

WALTHAM, Mass.–Akagera Medicines has received an additional $7.8 million in funding from the Gates Foundation to advance development of its experimental mRNA tuberculosis vaccine, bringing the foundation’s total funding commitment to approximately $9.79 million.

The expanded grant will support manufacturing and safety studies needed to prepare the vaccine candidate for its first human clinical trial.

The Waltham-based biopharmaceutical company is developing lipid nanoparticle (LNP) therapeutics and vaccines targeting infectious diseases that disproportionately affect populations in low- and middle-income countries.

The additional funding of $7,806,414 builds on an initial grant awarded in 2023 under a program focused on developing dendritic cell-targeted mRNA vaccines to prevent tuberculosis.

The latest investment will allow Akagera to move its vaccine program from preclinical research toward clinical development, including preparations for a future Phase 1 trial.

Tuberculosis remains one of the world’s deadliest infectious diseases, causing more than one million deaths annually. The disease continues to present significant public health challenges, particularly in regions with limited access to healthcare and preventive treatments.

The Bacillus Calmette-Guérin (BCG) vaccine, the only currently licensed tuberculosis vaccine, was developed more than a century ago. Although it provides protection against certain severe forms of tuberculosis in children, its effectiveness against pulmonary tuberculosis in adolescents and adults is limited and variable.

Researchers have identified the development of more effective vaccines for these populations as an important step toward reducing tuberculosis transmission and deaths.

Akagera’s experimental vaccine uses messenger RNA technology combined with specially engineered lipid nanoparticles designed to deliver tuberculosis antigens directly to dendritic cells.

Dendritic cells play a central role in activating the immune system by presenting antigens to T cells, which help coordinate immune responses against infections.

By targeting these cells, Akagera aims to stimulate stronger and longer-lasting T-cell responses against tuberculosis while potentially reducing the vaccine dose needed and improving tolerability.

Under the original 2023 grant, the company established the feasibility of its dendritic cell-targeting technology through preclinical studies.

According to Akagera, animal studies demonstrated strong immune responses using an mRNA vaccine candidate encoding nine distinct tuberculosis antigens. Laboratory testing also showed that human immune cells could recognize the tuberculosis antigens.

The expanded Gates Foundation funding will support several activities required before the vaccine can enter human testing.

These include process development and Good Manufacturing Practice (GMP) production of clinical trial materials, toxicology and safety pharmacology studies conducted under Good Laboratory Practice standards, and preparation of regulatory documentation.

The company plans to use the resulting data to support a future Investigational New Drug (IND) application or equivalent regulatory submission, which would be required before beginning a first-in-human Phase 1 clinical trial.

“This expanded support from the Gates Foundation marks the transition of our TB vaccine program from proof of concept to clinical readiness,” said Daryl Drummond, Ph.D., Co-Founder and Chief Scientific Officer of Akagera Medicines. “Targeting mRNA delivery to dendritic cells lets us focus on the immune response where it matters most for TB. With manufacturing and IND-enabling toxicology now funded, we have a clear path to our first-in-human study.”

The vaccine development program is part of Akagera’s broader efforts to develop treatments and preventive technologies for tuberculosis and other infectious diseases.

The company’s pipeline also includes AKG-100, an investigational long-acting tuberculosis therapeutic.

“Tuberculosis falls hardest on the communities with the least access to new medicines,” said Michael Fairbanks, Co-Founder and Executive Chairman of Akagera Medicines. “The Gates Foundation’s continued funding lets us advance a vaccine designed from the start for the people and places that need it most, alongside our long-acting TB therapeutic, AKG-100.”

The latest funding moves Akagera closer to clinical testing, although the vaccine remains investigational and has not yet been evaluated in humans.

Leave A Reply

Please enter your comment!
Please enter your name here